The most reliable finding in this entire field, more reliable than any efficacy number, is this: when people stop taking GLP-1 medications, most of the weight comes back.
It is treated, periodically, as an exposé. It should not be. It is the expected behavior of a treatment for a chronic, relapsing condition, and it is the same pattern you see when antihypertensives are stopped and blood pressure rises.
What the withdrawal data show
Extension and withdrawal studies have consistently found substantial regain following discontinuation, with much of the lost weight returning over the year or so afterward. Cardiometabolic improvements — blood pressure, lipids, glycemic markers — trend back toward baseline alongside it.
Nobody is surprised when blood pressure rises after stopping a blood pressure drug. The surprise about weight is a statement about how we think about obesity, not about how the drug works.
The mechanism is not mysterious. The drug suppresses appetite pharmacologically. Remove the drug, and appetite returns — often to a body that is now defending a lower weight with the full force of metabolic adaptation.
Why this belongs in the first appointment
The practical consequence is that “how long am I on this” is not a question to defer. It changes the arithmetic of the decision in three ways:
Financially. If the honest answer is “indefinitely,” then the relevant cost is not a six-month cost. Anyone budgeting for a course rather than a treatment is budgeting for the wrong thing.
Psychologically. People who begin believing they are taking a temporary intervention experience regain as personal failure. People who begin understanding it as ongoing treatment experience an interruption as an interruption.
Clinically. It shapes what you do during treatment — particularly around resistance training and dietary habits, which are the things that persist when the pharmacology does not.
It also argues for keeping a record of what the treatment was actually doing while it was doing it. The case for resuming — made to a clinician, or to an insurer — is far stronger from twelve months of data than from memory. Weight, dose, blood pressure, side effects, how you felt. Zenday is one way to hold it; the specific tool matters much less than having the file already built on the day the interruption arrives.
The situations where stopping is the right call
Plenty. Intolerable side effects. Pregnancy or planned pregnancy. A safety concern. Loss of coverage. Cost. A considered decision that the trade-off is no longer worth it.
Stopping is a legitimate choice. The point is not that nobody should stop — it is that stopping should be a decision made with accurate expectations rather than a surprise.
What we genuinely do not know
Whether intermittent or lower-dose maintenance regimens can hold weight with less drug is an open and important question, and one with obvious cost implications. Some clinicians already work this way in practice. The trial evidence is thinner than the confidence with which it is discussed online.
Whether behavioral and resistance-training work during treatment measurably reduces regain afterward is plausible, widely assumed, and not as well established as it should be by now.
Chronic
How obesity is classified by every major medical body
Indefinite
The realistic treatment horizon for most people who respond
Open
Whether reduced-dose maintenance works as well as full-dose
The framing that helps
The useful question is not “when do I get off this.” It is “what does the next ten years look like, and what is the plan when something interrupts it” — because something will. A job change, a formulary change, a shortage, a pregnancy, a move.
People who have thought about that in advance handle it as a logistics problem. People who have not handle it as a crisis. The alternative worth weighing honestly, because it does not depend on staying on anything, is surgery.
That conversation belongs in the first appointment, not the last one.